High‐dose therapy and autologous blood stem cell transplantation in multiple myeloma: Preliminary results of a randomized trial involving 167 patients
暂无分享,去创建一个
P. Ravaud | S. Chevret | X. Mariette | X. Troussard | V. Leblond | F. Dreyfus | J. Brouet | J. Fermand | Bélanger | M. Diviné | P. Ravaud | M. Diviné
[1] X. Mariette,et al. Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy. , 1994, Bone marrow transplantation.
[2] M. Gore,et al. High-dose melphalan for multiple myeloma: long-term follow-up data. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] F. Dreyfus,et al. Contamination of peripheral blood by monoclonal B cells following treatment of multiple myeloma by high‐dose chemotherapy , 1993, British journal of haematology.
[4] P. Ravaud,et al. High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. , 1993, Blood.
[5] S. Chevret,et al. The role of autologous blood stem cells in support of high-dose therapy for multiple myeloma. , 1992, Hematology/oncology clinics of North America.
[6] Y. Lévy,et al. Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. , 1989, Blood.